Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.
Clinical Trials
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says
Moderna and Merck’s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer by half after roughly three years, according to midstage trial data released Thursday.
MD Anderson at Cooper first in world to enroll patient in promising trial for metastatic melanoma
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte therapy.
Efficacy Shown for New Melanoma Therapeutic Vaccine
FRIDAY, Dec. 15, 2023 (HealthDay News) — In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.